These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7304394)

  • 1. Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimulation.
    Olsson SB; Edvardsson N
    Am Heart J; 1981 Nov; 102(5):864-71. PubMed ID: 7304394
    [No Abstract]   [Full Text] [Related]  

  • 2. Flecainide attenuates rate adaptation of ventricular repolarization in guinea-pig heart.
    Osadchii OE
    Scand Cardiovasc J; 2016; 50(1):28-35. PubMed ID: 26402340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New antiarrhythmia agents: propafenone and flecainide].
    Leclercq JF
    Presse Med; 1985 Mar; 14(12):685-9. PubMed ID: 3157964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed repolarization as antiarrhythmic action.
    Olsson SB; Edvardsson N
    Eur Heart J; 1988 Feb; 9 Suppl B():37-43. PubMed ID: 3286265
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiac electrophysiology of four new antiarrhythmic drugs--encainide, flecainide, lorcainide and tocainide.
    Camm AJ
    Eur Heart J; 1984 Sep; 5 Suppl B():75-9. PubMed ID: 6437820
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiarrhythmic and electrophysiologic actions of flecainide in animal models.
    Kvam DC; Banitt EH; Schmid JR
    Am J Cardiol; 1984 Feb; 53(5):22B-25B. PubMed ID: 6695815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart.
    Hodess AB; Follansbee WP; Spear JF; Moore EN
    J Cardiovasc Pharmacol; 1979; 1(4):427-39. PubMed ID: 94620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man.
    Hellestrand KJ; Bexton RS; Nathan AW; Spurrell RA; Camm AJ
    Br Heart J; 1982 Aug; 48(2):140-8. PubMed ID: 7093083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiologic properties of flecainide acetate.
    Estes NA; Garan H; Ruskin JN
    Am J Cardiol; 1984 Feb; 53(5):26B-29B. PubMed ID: 6695816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flecainide: a new prototype antiarrhythmic agent.
    Nappi JM; Anderson JL
    Pharmacotherapy; 1985; 5(4):209-21. PubMed ID: 3898035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological activation of IKr impairs conduction in guinea pig hearts.
    Larsen AP; Olesen SP; Grunnet M; Poelzing S
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):923-9. PubMed ID: 20163495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic drug effects on premature beats are partly determined by prior cardiac activation frequency in perfused guinea-pig heart.
    Osadchii OE
    Exp Physiol; 2020 May; 105(5):819-830. PubMed ID: 32175633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic effects of flecainide acetate on sinus node function, anomalous atrioventricular connections, and pacemaker thresholds.
    Hellestrand KJ; Nathan AW; Bexton RS; Camm AJ
    Am J Cardiol; 1984 Feb; 53(5):30B-38B. PubMed ID: 6695817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Electrophysiological effects of the new antiarrhythmic drug flecainide (R 818) in man (author's transl)].
    Seipel L; Abendroth RR; Breithardt G
    Z Kardiol; 1981 Jul; 70(7):524-9. PubMed ID: 7269731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia--study in the porcine in situ heart.
    Aupetit JF; Timour Q; Larbre JP; Loufoua-Moundanga J; Kioueh I; Lopez M; Faucon G
    Cardiovasc Drugs Ther; 1993 Apr; 7(2):217-23. PubMed ID: 8357775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes.
    Kjekshus J; Bathen J; Orning OM; Storstein L
    Am J Cardiol; 1984 Feb; 53(5):72B-78B. PubMed ID: 6421140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class 1 antiarrhythmic drugs--characteristic electrocardiographic differences when assessed by atrial and ventricular pacing.
    Milne JR; Hellestrand KJ; Bexton RS; Burnett PJ; Debbas NM; Camm AJ
    Eur Heart J; 1984 Feb; 5(2):99-107. PubMed ID: 6723689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flecainide: a new class Ic antidysrhythmic.
    Smith GH
    Drug Intell Clin Pharm; 1985 Oct; 19(10):703-7. PubMed ID: 3902429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiologic properties of a new antiarrhythmic drug--tocainide.
    Moore EN; Spear JF; Horowitz LN; Feldman HS; Moller RA
    Am J Cardiol; 1978 Apr; 41(4):703-9. PubMed ID: 645575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.